Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct;6(5):a005678. doi: 10.1101/mcs.a005678

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Takahashi et al.; Published by Cold Spring Harbor Laboratory Press

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial License, which permits reuse and redistribution, except for commercial purposes, provided that the original author and source are credited.

PMC Copyright notice

Figure 1. — Patient clinical course and germline mismatch repair (MMR) deficiency. (A) Patient clinical course, treatment, response, and timelines. (B) Patient genogram. (C) Hematoxylin and eosin staining (top) and MLH1 IHC (bottom). The red arrowhead in the bottom panel indicates loss of MLH1 expression on tumor cells, whereas the yellow arrowhead indicates intact MLH1 expression in normal hepatic cells. Black bars, 100 µm. (D) Integrated Genomics Viewer panel of germline MLH1 mutation. (E) Contrast-enhanced computed tomography (CT) scans pretreatment (left), 4 wk (middle) after treatment, and 8 wk (right) after treatment. Red arrows, yellow arrows, orange arrowheads, and light blue arrowheads indicate pleural lesions, right mediastinal lymph nodes, liver lesions, and right adrenal mass, respectively. (dMMR) Mismatch repair deficiency, (W) week, (PR) partial response, (PD) progressive disease, (COL) colorectal cancer, (BR) breast cancer, (THY) thyroid cancer, (UT) endometrial cancer, (H&E) hematoxylin and eosin, (IHC) immunohistochemistry staining, (Ref) reference, (Alt) alteration.